Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 3/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415054 | 1.00 | AGXT (0.40) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL660878 | 0.88 | AGXT (0.42) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL660879 | 0.88 | AGXT (0.42) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL6844411 | 0.88 | AGXT (0.42) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL966115 | 0.80 | AGXT (0.40) | AGXTLOXL2GLS | |
| SCHEMBL966114 | 0.80 | AGXT (0.40) | AGXTLOXL2GLS | |
| SCHEMBL4415047 | 0.79 | CYP2A6 (0.35) | AGXTCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL967191 | 0.79 | SIGMAR1 (0.35) | CYP2A6CASR | |
| SCHEMBL967189 | 0.79 | SIGMAR1 (0.35) | CYP2A6CASR | |
| SCHEMBL4494121 | 0.78 | PRSS1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395263-B1 | 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7183324-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183324-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-6956057-B2 | EP4 agonists as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050222094-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. | 2005-10-06 | — | — | US | disclosed |
| US-6538018-B1 | Method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound | ALLERGAN, INC. | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222094-A1 | Treatment of inflammatory bowel disease | SLC10A2, NR1H4, FABP2 | AGXT 180/4885CYP2A6 1292/4885ADRB2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.